Litigation Details for UCB, Inc. v. Mylan Technologies, Inc. (D. Del. 2017)

« Back to Dashboard

UCB, Inc. v. Mylan Technologies, Inc. (D. Del. 2017)

Docket	1:17-cv-00322	Date Filed	2017-03-24
Court	District Court, D. Delaware	Date Terminated	2019-08-26
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	UCB PHARMA GMBH
Patents	10,130,589; 10,350,174; 6,699,498; 6,884,434; 7,413,747; 8,246,979; 8,246,980; 8,617,591
Attorneys	Eleanor G. Tennyson
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for UCB, Inc. v. Mylan Technologies, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-03-24				External link to document
2017-03-24	10		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,699,498 B1; . (Attachments…2017 26 August 2019 1:17-cv-00322 830 Patent None District Court, D. Delaware	External link to document
2017-03-24	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,884,434 B1; 7,413,747 B2; 8,246,979…2017 26 August 2019 1:17-cv-00322 830 Patent None District Court, D. Delaware	External link to document
2017-03-24	92	SO ORDERED	209982), asserting U.S. Patent Nos. 10,130,589 ("the '589 Patent") and 10,350,174 ("…infringement of United States Patent Nos. 6,884,434 ("the ' 434 Patent"), 7,413 ,747 ("…quot;the ' 747 Patent"), 8,246,979 ("the ' 979 Patent"), 8,246,980 ("the …the '980 Patent"), and 8,617,591 ("the ' 591 Patent"), on May 24, 2017 (D.I. 1)…2019 (D.I. 82); WHEREAS the ' 434 Patent was the subject of a recent decision from the United	External link to document

UCB, Inc. v. Mylan Technologies, Inc. 1:17-cv-00322: Litigation Summary and Patent Analysis

Last updated: October 9, 2026

UCB, Inc. sued Mylan Technologies, Inc. in the U.S. District Court for the District of Delaware after Mylan filed an abbreviated new drug application seeking approval for a generic version of Neupro, UCB's rotigotine transdermal patch. The case concerned formulation and delivery-system patents covering rotigotine patches, rather than a biologic or biosimilar product. The public docket identifies the matter as Civil Action No. 1:17-cv-00322, assigned to Judge Richard G. Andrews.

The case was part of UCB's broader effort to protect Neupro against generic competition. Its commercial significance rested on the product's transdermal formulation, manufacturing controls, and patent protection for stabilized rotigotine delivery systems.

What drug and product were involved in UCB v. Mylan?

The dispute involved rotigotine transdermal system, marketed by UCB as Neupro.

Item	Detail
Brand	Neupro
Active ingredient	Rotigotine
Dosage form	Once-daily transdermal patch
FDA-approved indications	Parkinson's disease and moderate-to-severe primary restless legs syndrome
Innovator	UCB
Generic applicant	Mylan Technologies
Regulatory pathway	ANDA under the Hatch-Waxman Act
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-00322
Judge	Richard G. Andrews
Litigation type	Abbreviated new drug application patent litigation

Rotigotine is a non-ergoline dopamine agonist. Neupro's delivery system continuously releases rotigotine through the skin. The product's patent issues included the composition of the patch, stabilization of rotigotine, and the physical and chemical characteristics needed to maintain product performance during storage.

What patents protected Neupro in the Mylan litigation?

UCB asserted patents directed to rotigotine transdermal systems. The principal patent family associated with the litigation included U.S. Patent No. 8,232,414 and U.S. Patent No. 8,784,882.

Patent	General subject matter	Relevance
U.S. Patent No. 8,232,414	Rotigotine-containing transdermal therapeutic systems	Core formulation and delivery patent
U.S. Patent No. 8,784,882	Related rotigotine transdermal-system claims	Additional formulation and stability protection
Later UCB patents	Other rotigotine patch and product claims	Potentially relevant to later generic-entry analysis

The patents focused on the transdermal system rather than rotigotine as a molecule. That distinction matters because the active pharmaceutical ingredient itself was not the principal exclusivity barrier by the time of the Mylan case. UCB's protection depended on the patch formulation, the use of stabilizing components, and the system's ability to deliver rotigotine consistently.

Patent scope in this area generally turns on several technical limitations:

• The presence and amount of rotigotine.
• The polymer or adhesive matrix used to hold and release the drug.
• Antioxidant or stabilizing components.
• Chemical stability during storage.
• Patch construction and release characteristics.
• Dosage strength and delivery rate.
• Manufacturing conditions affecting polymorph, degradation, or uniformity.

When did Neupro lose regulatory and patent exclusivity?

Neupro's exclusivity did not end on a single date. Regulatory exclusivity, Orange Book patent protection, and practical generic-entry barriers operated on different timelines.

The earliest rotigotine patents were approaching or had reached the end of their terms when UCB brought the Mylan case. Later formulation patents extended the potential patent-exclusion period beyond the expiration of earlier molecule and product patents.

Patent-term timeline

Event	Approximate timing	Commercial effect
Neupro U.S. approval	2007	UCB obtained FDA approval for rotigotine patches
Earlier product patents	Early 2020s	Initial patent barriers began expiring
U.S. Patent No. 8,232,414	2026 term commonly reported	Continued protection for covered formulations
U.S. Patent No. 8,784,882	2026 term commonly reported	Related formulation protection
Mylan ANDA litigation	Filed in 2017	Triggered Hatch-Waxman litigation and the statutory stay
Generic competition	Dependent on FDA approval and litigation resolution	Entry could occur after patent, settlement, or judgment resolution

The precise expiration date for each patent depends on the patent's term adjustment, term extension, disclaimer history, and any applicable terminal disclaimer. Commercial analysis should therefore use the USPTO Patent Center and the current FDA Orange Book rather than relying only on the nominal 20-year term.

What was Mylan's Paragraph IV challenge?

Mylan's ANDA filing likely included a Paragraph IV certification for UCB's listed Neupro patents. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

UCB's complaint followed the statutory framework under 21 U.S.C. § 355(j)(5)(B)(iii) and 35 U.S.C. § 271(e)(2). Filing the complaint triggered the Hatch-Waxman 30-month stay of FDA approval, subject to earlier termination through a court decision or settlement.

The principal legal disputes in a rotigotine patch case typically include:

1. Whether Mylan's proposed patch falls within the asserted claim language.
2. Whether the asserted claims are anticipated or obvious.
3. Whether the claimed stabilizer and formulation limitations were disclosed in prior art.
4. Whether a skilled artisan would have had a reasonable expectation of success in formulating a stable rotigotine patch.
5. Whether any asserted claims are invalid for lack of written description or enablement.
6. Whether Mylan's ANDA product meets each limitation, based on the ANDA itself and related manufacturing information.

A Paragraph IV filing does not itself establish that the generic product infringes. It creates the statutory mechanism for the patent holder to litigate before commercial approval.

What was the litigation status and outcome?

The action was filed in the District of Delaware as UCB, Inc. v. Mylan Technologies, Inc., No. 1:17-cv-00322. Public docket materials identify the case as ANDA litigation concerning Mylan's proposed generic rotigotine transdermal system.

The public record does not establish a reported final merits judgment in this action comparable to a published Federal Circuit decision holding the asserted patents valid and infringed against Mylan. The case should therefore not be characterized as a definitive merits victory for either party without citing the operative dismissal, settlement order, or final judgment from the docket.

The key procedural consequences were:

• UCB obtained the right to litigate Mylan's Paragraph IV allegations before FDA approval.
• The case created a statutory approval delay under Hatch-Waxman.
• Mylan's commercial launch depended on the resolution of the litigation and the terms of any settlement.
• The action did not eliminate the broader patent risk associated with later-filed or separately listed UCB patents.

Related appellate and district-court precedent

UCB's rotigotine patent portfolio was litigated against other generic companies, including Actavis and Watson. Those cases addressed overlapping patent-family issues and provide important context for assessing validity and claim scope. They should not be treated as direct judgments against Mylan unless the specific patent, claims, product, and procedural posture match the Mylan action.

In particular, prior litigation involving the '414 patent is relevant to obviousness and formulation arguments. Patent-family decisions can affect settlement leverage, but collateral-estoppel analysis requires a claim-by-claim comparison and an identity or privity analysis.

What Orange Book patents covered Neupro?

The FDA Orange Book is the primary source for determining which patents UCB listed against Neupro and which patents required certification in an ANDA.

Orange Book analysis should distinguish among:

• Drug-substance patents.
• Drug-product patents.
• Method-of-use patents.
• Formulation and delivery-system patents.
• Patents that remain listed but have expired.
• Patents subject to pediatric exclusivity or patent-term extension.
• Patents delisted, corrected, or affected by FDA listing decisions.

For Neupro, the economically relevant listings were formulation and transdermal-system patents. Method-of-use patents could affect labeled indications, but they would not necessarily block an ANDA with appropriate section viii carve-outs if the generic applicant could lawfully omit the patented use.

The current Orange Book listing should be checked for:

• Patent numbers.
• Expiration dates.
• Use codes.
• Delisting history.
• Pediatric exclusivity.
• Any changes after the Mylan litigation.

What formulation patents protected rotigotine patches?

The formulation patents were important because rotigotine is sensitive to chemical and physical stability issues. A patch must maintain drug uniformity, prevent unacceptable degradation, and release the active ingredient at a controlled rate.

Potential formulation barriers include:

Stabilized rotigotine compositions

Claims may require an antioxidant or other stabilizing agent. These claims can be difficult for a generic applicant if the ANDA formulation necessarily includes the claimed component or performs the claimed stabilizing function.

Adhesive-matrix systems

A patch may use an adhesive matrix that acts both as the drug reservoir and as the skin-contact layer. Claims may distinguish among acrylic, silicone, polyisobutylene, or other adhesive systems.

Release characteristics

Claims may define the amount of rotigotine delivered over a specified period or the physical structure of the patch. Such limitations can create infringement questions that are difficult to resolve solely from the public label.

Manufacturing and storage stability

Manufacturing controls can affect polymorphic form, degradation products, content uniformity, and release rates. These issues may support confidential discovery into Mylan's ANDA, batch records, and stability data.

How strong was UCB's patent estate?

UCB's Neupro estate was commercially meaningful but narrower than a basic compound patent.

Strength factor	Assessment
Compound protection	Limited once early rotigotine rights expired
Formulation protection	Material, particularly for stabilized patch systems
Manufacturing protection	Potentially significant but dependent on claim language and proof
Method-of-use protection	Useful for selected indications, subject to carve-out rules
Orange Book leverage	High during the 30-month stay
Design-around risk	Moderate because transdermal systems can be modified
Generic substitution risk	High after formulation patents and litigation barriers fall away

The estate's main strength came from the difficulty of producing a commercially viable rotigotine patch that avoided every asserted formulation limitation while maintaining equivalent delivery and stability. Its weakness was that formulation claims are more vulnerable than broad compound claims to prior-art and design-around arguments.

The prior-art record for transdermal dopamine agonists, adhesive matrices, antioxidants, and controlled-release systems could support obviousness defenses. UCB's counterargument would focus on the combined formulation limitations, rotigotine's specific stability problems, and the absence of a predictable path to the claimed result.

Did the case involve a biosimilar challenge?

No. The case involved a small-molecule generic drug, not a biosimilar.

Mylan proceeded through the ANDA pathway. Biosimilar litigation under the Biologics Price Competition and Innovation Act was not relevant to rotigotine or Neupro. The applicable framework was Hatch-Waxman, including Paragraph IV certification, the 30-month stay, and potential section viii statements for method-of-use patents.

What generic-entry risks existed for UCB?

UCB faced several generic-entry scenarios:

Entry after settlement

A settlement could establish a licensed entry date before full patent expiration. The economic result would depend on whether Mylan received an exclusive or nonexclusive launch right and whether other generic applicants could enter earlier.

Entry after invalidity or noninfringement

If Mylan prevailed on all asserted patents, FDA approval could proceed once regulatory requirements were satisfied. A noninfringement ruling could be particularly important because it would leave the patents in force against other products while allowing Mylan's formulation to launch.

Entry after patent expiration

Expiration of the remaining formulation patents would remove the principal Orange Book barrier, subject to regulatory approval and any unexpired method-of-use restrictions.

Design-around launch

A generic applicant could modify the adhesive, antioxidant, patch architecture, dosage strength, or manufacturing process. A successful design-around would reduce infringement exposure but still require bioequivalence and product-quality approval.

Which companies challenged Neupro patents?

UCB faced generic challenges from multiple companies, including Mylan and other major generic manufacturers. Related litigation involving Actavis and Watson is relevant because overlapping patent-family issues can influence:

• Obviousness arguments.
• Claim construction.
• Settlement value.
• The likelihood of successful design-around products.
• The scope of UCB's enforceable patent rights.

Competition was not limited to a single ANDA applicant. Once one applicant established a viable route around the patent estate, additional generic manufacturers could use the same legal and technical analysis.

What revenue exposure did the litigation create?

Neupro revenue exposure depended on the timing and number of generic launches. Transdermal products can experience rapid price erosion after generic entry, although the extent depends on:

• Number of approved generic suppliers.
• Pharmacy substitution practices.
• Payer contracting.
• Wholesale acquisition cost.
• Remaining branded demand.
• Product shortages or manufacturing limitations.
• Whether generic products are therapeutically equivalent and substitutable.

A single first entrant can reduce branded volume before multiple generic suppliers launch. If UCB retained a licensed generic or authorized-generic arrangement, it could offset part of the erosion through supply economics, but the public case record alone does not establish the commercial terms of any settlement or licensing arrangement.

Did UCB and Mylan enter a settlement or licensing deal?

A settlement should be confirmed from the operative docket documents and any publicly filed agreement. The case number alone does not establish the terms of a settlement, launch date, royalty structure, authorized-generic arrangement, or release of claims.

No commercial conclusion should be drawn from the existence of a dismissal alone. A dismissal may reflect a conventional settlement, a consent judgment, a license, a transfer of the ANDA, or another resolution. The legally relevant documents are the stipulation of dismissal, settlement agreement if filed, consent judgment, and any order resolving pending motions.

How does the Mylan case compare with competing Neupro litigation?

Issue	UCB v. Mylan	Related UCB generic cases
Product	Rotigotine transdermal system	Rotigotine transdermal systems
Statute	Hatch-Waxman	Hatch-Waxman
Main risk	Formulation and delivery-system patents	Similar formulation and stability issues
Regulatory effect	30-month stay and ANDA approval delay	Same statutory framework
Biosimilar relevance	None	None
Precedential value	Limited unless a merits decision was issued	Depends on patent and claim overlap
Commercial effect	Delayed or conditioned Mylan entry	Broader timing of generic competition

The most important analytical mistake is to treat a decision in another UCB case as automatically controlling the Mylan action. Patent validity and infringement are claim-specific. The same patent may produce different results depending on the ANDA formulation, asserted claims, expert evidence, and procedural record.

Key Takeaways

• UCB v. Mylan, No. 1:17-cv-00322, was Hatch-Waxman litigation over Mylan's proposed generic rotigotine transdermal patch.
• Neupro's principal protection came from formulation, stabilization, adhesive-matrix, and transdermal-delivery patents.
• The dispute did not involve a biosimilar or biologic product.
• UCB's relevant patent estate was narrower than a compound patent estate and was exposed to obviousness and design-around challenges.
• The action triggered the Hatch-Waxman approval stay and delayed Mylan's potential market entry.
• The existence and terms of any settlement, license, authorized-generic arrangement, or agreed launch date must be determined from the operative docket documents.
• Related UCB litigation involving Actavis and Watson is useful context but does not automatically decide Mylan's claims.
• Orange Book status, terminal disclaimers, patent-term adjustment, and later patent listings are central to any current exclusivity analysis.

FAQs

What was Mylan's proposed product in UCB v. Mylan?

Mylan sought approval for a generic rotigotine transdermal system, intended to compete with UCB's Neupro patch.

Was UCB v. Mylan a patent-infringement case or an ANDA case?

It was ANDA litigation under the Hatch-Waxman Act. UCB's complaint treated Mylan's ANDA filing as an artificial act of infringement under 35 U.S.C. § 271(e)(2).

Did the case concern rotigotine's chemical compound patent?

The principal dispute concerned rotigotine transdermal formulations and delivery systems, not only the underlying rotigotine molecule.

Can a generic omit a patented Neupro indication?

A generic applicant may use a section viii statement to carve out a patented method of use when the remaining labeling and product conduct comply with the statutory requirements. That approach does not avoid formulation or product patents.

What is the principal business risk from Neupro generic entry?

The principal risk is rapid branded-volume and price erosion once an FDA-approved, therapeutically equivalent rotigotine patch can enter without an effective Orange Book patent or settlement restriction.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
2. U.S. Food and Drug Administration. (n.d.). Neupro (rotigotine) prescribing information.
3. U.S. Patent and Trademark Office. (n.d.). U.S. Patent No. 8,232,414.
4. U.S. Patent and Trademark Office. (n.d.). U.S. Patent No. 8,784,882.
5. U.S. District Court for the District of Delaware. (2017). UCB, Inc. v. Mylan Technologies, Inc., No. 1:17-cv-00322.
6. U.S. Code. (2024). 21 U.S.C. § 355.
7. U.S. Code. (2024). 35 U.S.C. § 271.